Curis (CRIS) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings or view top-rated stocks.

2 analysts have issued 12 month target prices for Curis' stock. Their CRIS share price forecasts range from $3.00 to $6.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 893.4% from the stock's current price.
View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts.

Curis' stock was trading at $0.55 at the beginning of the year. Since then, CRIS stock has decreased by 17.6% and is now trading at $0.4530.
View the best growth stocks for 2023 here.

Curis saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,160,000 shares, a drop of 7.2% from the August 15th total of 1,250,000 shares. Based on an average daily trading volume, of 323,300 shares, the days-to-cover ratio is currently 3.6 days.
View Curis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CRIS earnings forecast.

Curis, Inc. (NASDAQ:CRIS) posted its earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The biotechnology company earned $2.20 million during the quarter, compared to analysts' expectations of $2.57 million. Curis had a negative trailing twelve-month return on equity of 116.63% and a negative net margin of 471.71%.

Shares of Curis reverse split on the morning of Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 29th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Curis' stock is owned by a variety of retail and institutional investors. Top institutional investors include M28 Capital Management LP (5.10%), Renaissance Technologies LLC (1.43%), BlackRock Inc. (0.99%), Focused Wealth Management Inc (0.54%), Arnhold LLC (0.37%) and Northern Trust Corp (0.13%).
View institutional ownership trends.

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRIS stock can currently be purchased for approximately $0.45.

Curis (NASDAQ:CRIS) has a market capitalization of $53.32 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.